The Fifth International Conference
CHALLENGES FOR EFFICIENT HEALTH CARE IN CENTRAL AND EASTERN EUROPE
PRESENTATIONS
Using HTA for making legitimate reimbursement decisions in health care Wija Oortwijn PhD, Partner at ECORYS NL Rotterdam, The Netherlands
HTA as advisory tool for investors – MedInvest Scanner databases Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland
Central and Eastern Europe - Diversity to tame, Market Access potential to unveil Norbert Wilk, Arcana Institute, Poland
HTA as advisory tool for investors – MedInvest Scanner databases Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland
Central and Eastern Europe - Diversity to tame, Market Access potential to unveil Norbert Wilk, Arcana Institute, Poland
Real world evidence for real world challenges Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK
Patient registries as a tool for improvement in the quality of treatment and for appropriate planning and allocation of resources Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia
Pharmaceutical Policy in MICs – Challenges and Priorities Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank
Pragmatic Reimbursement Decision Making Framework – A Key for Resolving Reimbursement Impasse in SerbiaDávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary
Patient registries as a tool for improvement in the quality of treatment and for appropriate planning and allocation of resources Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia
Pharmaceutical Policy in MICs – Challenges and Priorities Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank
Pragmatic Reimbursement Decision Making Framework – A Key for Resolving Reimbursement Impasse in SerbiaDávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary
Western European markets for biosimilar drugs; worth differentiation Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow,
UK; Karolinska Institute, Sweden
Access to innovation – where is Serbia today? Bojan Trkulja MD, Managing Director at INOVIA, Serbia
Challenges associated with high prices of new cancer medicines; potential ways forward for CEE countries based on HTA principles Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden
Why are Orphan Drugs different? – Achieving sustainable access for orphan drugs Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany
Targeted therapies in oncology – a Serbian pharmacoeconomic perspective Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
Access to innovation – where is Serbia today? Bojan Trkulja MD, Managing Director at INOVIA, Serbia
Challenges associated with high prices of new cancer medicines; potential ways forward for CEE countries based on HTA principles Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden
Why are Orphan Drugs different? – Achieving sustainable access for orphan drugs Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany
Targeted therapies in oncology – a Serbian pharmacoeconomic perspective Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
How public private partnerships can address challenges in patient access Stephan Korte, Novartis
Improving Polish HTA guidelines to better serve the decision-maker Jakub Adamski, Arcana Institute, Poland
HTA: Effectively capturing the patients voice Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK
Croatian perspective cost effectiveness analysis of HCV “Interferon free“ therapy Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia
WORKSHOP II: WAR GAMING – COST EFFECTIVENESS ANALYSIS AND CENTRAL TENDERING Mark Parker, MSc, Health Economics Unit, University of Liverpool Management School, UK
Rheumatoid arthritis Results
Chronic hepatitis C therapy Results
Improving Polish HTA guidelines to better serve the decision-maker Jakub Adamski, Arcana Institute, Poland
HTA: Effectively capturing the patients voice Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK
Croatian perspective cost effectiveness analysis of HCV “Interferon free“ therapy Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia
WORKSHOP II: WAR GAMING – COST EFFECTIVENESS ANALYSIS AND CENTRAL TENDERING Mark Parker, MSc, Health Economics Unit, University of Liverpool Management School, UK
Rheumatoid arthritis Results
Chronic hepatitis C therapy Results